
Involving patients more meaningfully in the industry's activities means getting more serious about their emotional wellbeing.
Involving patients more meaningfully in the industry's activities means getting more serious about their emotional wellbeing.
BMS executive shares his perspectives on the current biomarker landscape, the role of translational medicine in accelerating this area of study, and how BMS is working to advance biomarker research across their R&D portfolio.
Q&A explores the evolution of the patient-centric supply chain and how it's poised to impact the clinical trials landscape.
Published: February 13th 2025 | Updated: March 4th 2025
Published: February 19th 2025 | Updated: February 26th 2025
Published: March 24th 2023 | Updated:
Published: April 28th 2021 | Updated:
Published: July 26th 2024 | Updated:
Published: January 31st 2024 | Updated: